Micafungin Accord (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is required for the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. By blocking this pathway, the drug weakens the cell wall, leading to osmotic instability and cell lysis, resulting in fungicidal activity against most Candida species.

The dosage of Micafungin Accord is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and severity of infection. Healthcare providers follow established clinical guidelines and adjust the regimen as needed; patients should not alter the dose without medical advice.

The safety of micafungin in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and the drug should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as micafungin may be excreted in breast milk.

To request Micafungin Accord, visit the product page on gnhindia.com, submit an enquiry specifying the required quantity, and provide institutional or trade credentials. GNH India’s commercial team will verify eligibility, then respond with pricing, availability, shipping details—including any cold‑chain requirements—and assist with import documentation for hospitals, pharmacies, or procurement agencies.

Micafungin belongs to the echinocandin class, which differs from azoles and polyenes by targeting the fungal cell‑wall synthesis pathway rather than ergosterol synthesis or membrane integrity. Compared with azoles, echinocandins generally have fewer drug‑drug interactions and a lower risk of hepatotoxicity, but they are administered intravenously and are primarily active against Candida species.

Micafungin Accord should be stored at 2‑8 °C (refrigerated) in its original packaging to protect from light. Do not freeze or shake the solution. Prior to administration, the product may be allowed to reach room temperature briefly, but it must be used within the time frame specified in the manufacturer’s instructions.

Micafungin Accord is supplied as an intravenous solution and is administered by slow infusion through a suitable venous access device. The infusion rate and duration are determined by the prescribing clinician, typically over 30‑60 minutes, and the medication should be administered in a clinical setting with appropriate monitoring.

The most serious adverse events linked to micafungin include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, acute renal failure, and serious infusion‑related reactions like hypotension or bronchospasm. Prompt recognition and discontinuation of the drug are essential if any of these events occur.

Micafungin Accord is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled renal failure, or those receiving interacting medications that cannot be managed. Clinical judgment should determine suitability for each patient.